Company profile

Astellas Pharma

Diversified pharma

4503 · TSE · Japan

Public Market Listing

4503TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Astellas Pharma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(8 total)
8Total Assets
5Approved
1Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
Showing 8 of 8 assets
Target & Modality
Avacincaptad pegol(Izervay)
Approved
Complement C5Other
Age-Related Macular Degeneration
Bixalomer(Kiklin)
Approved
Phosphate binderSmall molecule
Chronic Kidney Disease
Gilteritinib
Approved
FLT3Small molecule
Non-Small Cell Lung CancerAcute Myeloid Leukemia
Ipragliflozin(Suglat)
Approved
SGLT2Small molecule
Type 2 Diabetes
Roxadustat(Evrenzo)
Approved
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease
Setidegrasib
Phase 3
KRAS G12DProtein / enzyme therapeutic
Non-Small Cell Lung Cancer
Enfortumab Vedotin
Phase 2
Nectin-4Antibody–drug conjugate
Non-Small Cell Lung Cancer
ASP5834
Phase 1
Pan-KRASSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.